vascular endothelial growth factor receptors

Summary

Summary: A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular Ig-like domains which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.

Top Publications

  1. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
  2. ncbi Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
    F Shalaby
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Nature 376:62-6. 1995
  3. ncbi Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    N Engl J Med 356:115-24. 2007
  4. ncbi The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions
    Hiroyuki Takahashi
    Division of Genetics, Institute of Medical Science, University of Tokyo, 4 6 1 Shirokane dai, Minato ku, Tokyo, 108 8639, Japan
    Clin Sci (Lond) 109:227-41. 2005
  5. ncbi Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma
    Jeffrey W Walter
    Department of Genetics, Duke University Medical Center, Durham, NC 27710, USA
    Genes Chromosomes Cancer 33:295-303. 2002
  6. ncbi VEGF is required for growth and survival in neonatal mice
    H P Gerber
    Departments of Cardiovascular Research and Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Development 126:1149-59. 1999
  7. ncbi VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 417:954-8. 2002
  8. ncbi Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
    D Lyden
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Nat Med 7:1194-201. 2001
  9. ncbi VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding
    Shay Soker
    Department of Urology, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Cell Biochem 85:357-68. 2002
  10. ncbi Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nature 380:439-42. 1996

Detail Information

Publications314 found, 100 shown here

  1. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
    ..VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration...
  2. ncbi Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
    F Shalaby
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Nature 376:62-6. 1995
    ..These results indicate that Flk-1 is essential for yolk-sac blood-island formation and vasculogenesis in the mouse embryo...
  3. ncbi Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    N Engl J Med 356:115-24. 2007
    ..Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted...
  4. ncbi The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions
    Hiroyuki Takahashi
    Division of Genetics, Institute of Medical Science, University of Tokyo, 4 6 1 Shirokane dai, Minato ku, Tokyo, 108 8639, Japan
    Clin Sci (Lond) 109:227-41. 2005
    ..Recent progress in the molecular and biological understanding of the VEGF/VEGFR system provides us with novel and promising therapeutic strategies and target proteins for overcoming a variety of diseases...
  5. ncbi Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma
    Jeffrey W Walter
    Department of Genetics, Duke University Medical Center, Durham, NC 27710, USA
    Genes Chromosomes Cancer 33:295-303. 2002
    ..These results suggest that one potential mechanism involved in hemangioma formation is the alteration of the VEGF signaling pathway in endothelial and/or pericytic cells...
  6. ncbi VEGF is required for growth and survival in neonatal mice
    H P Gerber
    Departments of Cardiovascular Research and Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Development 126:1149-59. 1999
    ..Thus, VEGF is essential for growth and survival in early postnatal life. However, in the fully developed animal, VEGF is likely to be involved primarily in active angiogenesis processes such as corpus luteum development...
  7. ncbi VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 417:954-8. 2002
    ..Not only ligands selective for VEGF and VEGFR-2 but also VEGFR-1 agonists rescued survival and repopulation of VEGF-deficient HSCs, revealing a function for VEGFR-1 signalling during haematopoiesis...
  8. ncbi Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
    D Lyden
    Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Nat Med 7:1194-201. 2001
    ..These data demonstrate that recruitment of VEGF-responsive BM-derived precursors is necessary and sufficient for tumor angiogenesis and suggest new clinical strategies to block tumor growth...
  9. ncbi VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding
    Shay Soker
    Department of Urology, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Cell Biochem 85:357-68. 2002
    ..These complexes are formed on the surface of EC and in a juxtacrine manner via association of tumor cell NRP1 and EC KDR...
  10. ncbi Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nature 380:439-42. 1996
    ..Angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Furthermore, VEGF-null embryonic stem cells exhibit a dramatically reduced ability to form tumours in nude mice...
  11. ncbi Vascular endothelial growth factor as a target for anticancer therapy
    Napoleone Ferrara
    Genentech, Inc, South San Francisco, California 94080, USA
    Oncologist 9:2-10. 2004
    ..Of these, bevacizumab, a humanized monoclonal antibody directed at VEGF, is the most advanced in clinical development and has shown promising results in clinical trials...
  12. pmc Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms
    Ingeborg Stalmans
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Catholic University Leuven, Leuven, Belgium
    J Clin Invest 109:327-36. 2002
    ..These findings reveal distinct roles of the various VEGF isoforms in vascular patterning and arterial development in the retina...
  13. ncbi Vascular endothelial growth factor (VEGF) and its receptors
    G Neufeld
    Department of Biology, Technion, Israel Institute of Technology, Technion City, Haifa 32000, Israel
    FASEB J 13:9-22. 1999
    ....
  14. ncbi Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer
    Carolyn Cao
    Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 5671, USA
    Cancer Res 66:11409-15. 2006
    ..Clinical trials are needed to determine the potential of this combination therapy in patients with locally advanced lung cancer...
  15. ncbi Vascular endothelial growth factor effects on nuclear factor-kappaB activation in hematopoietic progenitor cells
    M M Dikov
    The Vanderbilt Cancer Center and Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-6838, USA
    Cancer Res 61:2015-21. 2001
    ..Therapeutic strategies aimed at overcoming VEGF-mediated defects in immune induction in tumor-bearing hosts will need to target this kinase-independent pathway...
  16. ncbi Coordinated induction of VEGF receptors in mesenchymal cell types during rat hepatic wound healing
    V Ankoma-Sey
    UCSF Liver Center and Department of Medicine, University of California, San Francisco, USA
    Oncogene 17:115-21. 1998
    ..These findings suggest that the cellular targets of VEGF in liver may not be confined to sinusoidal endothelial cells, and that VEGF responses reflect combined effects on both hepatic stellate cells and sinusoidal endothelium...
  17. ncbi Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain
    J M Krum
    Department of Anatomy and Cell Biology, The George Washington University Medical Center, Washington, DC 20037, USA
    Neuroscience 110:589-604. 2002
    ..From these results we suggest that administered VEGF has heretofore unanticipated pleiotrophic effects in the adult CNS...
  18. ncbi The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development
    D Liang
    Department of Biological Sciences, National University of Singapore, Singapore 119260
    Mech Dev 108:29-43. 2001
    ..Moreover, these effects are most dramatic when both vegf isoforms are co-expressed, indicating a synergistic effect of the expression of the two forms of the VEGF protein...
  19. ncbi Pathophysiological consequences of VEGF-induced vascular permeability
    Sara M Weis
    Department of Pathology and Moores UCSD Cancer Center, University of California, San Diego, La Jolla, California 92093 0803, USA
    Nature 437:497-504. 2005
    ..Therefore, by blocking the vascular permeability promoting effects of VEGF it may be feasible to reduce tissue injury after ischaemic disease and minimize the invasive properties of circulating tumour cells...
  20. ncbi Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis
    M A McTigue
    Agouron Pharmaceuticals, 3565 General Atomics Court, San Diego, CA 92121, USA
    Structure 7:319-30. 1999
    ..VEGFRs are receptor tyrosine kinases that, like the platelet-derived growth factor receptors (PDGFRs), contain a large insert within the kinase domain...
  21. ncbi Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
    S Soker
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cell 92:735-45. 1998
    ..We propose that neuropilin-1 is a novel VEGF receptor that modulates VEGF binding to KDR and subsequent bioactivity and therefore may regulate VEGF-induced angiogenesis...
  22. ncbi Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade
    Rubin M Tuder
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Am J Respir Cell Mol Biol 29:88-97. 2003
    ..Oxidative stress and apoptosis, which cause lung cellular destruction in emphysema induced by VEGF receptor blockade, may be important mediators common to human and experimental emphysema...
  23. ncbi Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma
    M Hoshino
    Second Department of Internal Medicine, Toho University School of Medicine, 6-11-1, Omori-nishi, Ota-ku, Tokyo, Japan
    J Allergy Clin Immunol 107:1034-8. 2001
    ..CONCLUSION: These findings provide evidence that VEGF may play an important role in angiogenesis and subsequent airway remodeling in bronchial asthma...
  24. ncbi Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies
    S Helske
    Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, PL 140, 00290 Helsinki, Finland
    Mol Hum Reprod 7:205-10. 2001
    ..These results suggest that low maternal serum PlGF and increased placental expression of its receptor VEGFR-1 are associated with pre-eclampsia and FGR...
  25. pmc Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis
    Xiao Yong Man
    Department of Dermatology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, P R China
    Mol Med 12:127-36. 2006
    ..Taken together, our results suggest that the expression of VEGFRs and NRPs on keratinocytes may constitute important regulators for its activity and may possibly be responsible for the autocrine signaling in the epidermis...
  26. ncbi Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165
    Chenghua Gu
    Department of Neuroscience, Howard Hughes Medical Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Biol Chem 277:18069-76. 2002
    ..These results establish the identity of contact sites between Npn-1 and its semaphorin ligands, and they provide a foundation for understanding how Npn-1 functions as a receptor for distinct classes of ligands in vivo...
  27. pmc Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors
    Sunyoung Lee
    Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles 90095, USA
    J Cell Biol 169:681-91. 2005
    ..Our findings support the view that matrix-bound VEGF and nontethered VEGF provide different signaling outcomes. These findings reveal a novel aspect in the regulation of extracellular VEGF that holds significance for vascular patterning...
  28. ncbi Vascular endothelial growth factor (VEGF) signaling in tumor progression
    Robert Roskoski
    Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116A, Box 19, Horse Shoe, NC 28742, USA
    Crit Rev Oncol Hematol 62:179-213. 2007
    ..Owing to the importance of angiogenesis in tumor progression, inhibition of VEGF signaling represents an attractive cancer treatment...
  29. ncbi Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src
    H He
    Vascular Biology Center, The Medical College of Georgia, Augusta, Georgia 30912 2500, USA
    J Biol Chem 274:25130-5. 1999
    ..These results suggest that NO and PGI(2) function in parallel in mediating the effects of VEGF...
  30. ncbi Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
    Keith T Flaherty
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 7:496-501. 2008
    ..Sorafenib is a novel RAF and VEGF receptor tyrosine kinase inhibitor. We conducted this study to (a) determine if sorafenib is anti-angiogenic, and (b) to relate anti-angiogenic effect to outcome...
  31. ncbi VEGF receptor signalling - in control of vascular function
    Anna Karin Olsson
    Department of Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjöldv 20, 751 85 Uppsala, Sweden
    Nat Rev Mol Cell Biol 7:359-71. 2006
    ..Recent insights have shed light onto VEGFR signal transduction and the interplay between different VEGFRs and VEGF co-receptors in development, adult physiology and disease...
  32. ncbi Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor
    Jen Ruey Tang
    Pediatric Heart Lung Center, University of Colorado School of Medicine, Denver Colorado 80218, USA
    Am J Physiol Lung Cell Mol Physiol 287:L344-51. 2004
    ..We speculate that decreased NO production contributes to PH and decreases distal lung growth caused by impaired VEGF signaling...
  33. ncbi The splice variants of vascular endothelial growth factor (VEGF) and their receptors
    C J Robinson
    The Cancer Research Campaign Department of Drug Development and the CRC and University of Manchester Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital, Manchester, M20 4BX, UK
    J Cell Sci 114:853-65. 2001
    ..HSPGs have a wide variety of functions, such as the ability to partially restore lost function to damaged VEGF(165) and thereby prolonging its biological activity...
  34. ncbi Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    Sandrine Faivre
    Department of Medicine, Gustave Roussy Institute, Villejuif, France
    J Clin Oncol 24:25-35. 2006
    ..To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies...
  35. ncbi ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    Stephen R Wedge
    Department of Cancer and Infection Research, AstraZeneca, Cheshire SK10 4TG, United Kingdom
    Cancer Res 62:4645-55. 2002
    ..4 cm(3) volume. ZD6474 is currently in Phase I clinical development as a once-daily oral therapy in patients with advanced cancer...
  36. ncbi Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy
    S Shinkaruk
    INSERM U443 Bio Organic Chemistry Group, University Victor Segalen Bordeaux 2, F33076 Bordeaux Cedex France
    Curr Med Chem Anticancer Agents 3:95-117. 2003
    ..In conclusion, this bibliographic study allows to situate works of medicinal chemistry in the context of present knowledge concerning the vascular endothelial growth factor (VEGF) and its role in angiogenesis...
  37. ncbi Expression of vascular endothelial growth factor receptors in the human endometrium: modulation during the menstrual cycle
    G Meduri
    INSERM U460, Remodelage Vasculaire, CHU Xavier Bichat, 75870 Paris Cedex, France
    Biol Reprod 62:439-47. 2000
    ..The molecular mechanisms concerning these regulations will require further investigation...
  38. ncbi Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121)
    G B Whitaker
    Department of Cardiovascular Research, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Road, Mason, Ohio 45040, USA
    J Biol Chem 276:25520-31. 2001
    ..Taken together, these data suggest a receptor-clustering role for Npn-1, as opposed to Npn-1 behaving as an affinity-converting subunit...
  39. ncbi Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma
    Mitra Fakhari
    Department of Pediatric Surgery, University of Vienna, Vienna, Austria
    Cancer 94:258-63. 2002
    ..Neuropilin-1 and 2 (NRP) are novel specific receptors of VEGF(165), whose role is unknown in human neuroblastoma...
  40. ncbi Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma
    M Fakhari
    Laboratory for Cardiovascular Research, Departments of Anatomy, Pediatric Surgery, and Molecular Biology, University of Vienna, Vienna, Austria
    J Pediatr Surg 37:582-7. 2002
    ..The interaction of VEGF and its receptors at gene and protein levels in neuroblastoma remains widely unknown...
  41. ncbi Expression of vascular endothelial growth factor receptors in smooth muscle cells
    A Ishida
    Department of Molecular Biology, The Hope Heart Institute, Seattle, Washington 98122, USA
    J Cell Physiol 188:359-68. 2001
    ..In conclusion, our studies demonstrate the presence of VEGF receptors on VSMCs that are functional. These studies also indicate that in vivo, VEGF may play a role in modulating the response of VSMCs...
  42. pmc The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching
    Steven Suchting
    Institut National de la Sante et de la Recherche Medicale, U833, 75005 Paris, France
    Proc Natl Acad Sci U S A 104:3225-30. 2007
    ..Taken together, these data reveal Dll4 as a negative regulator of vascular sprouting and vessel branching that is required for normal vascular network formation during development...
  43. pmc Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis
    Hideyasu Oh
    Department of Ophthalmology and Visual Sciences, Graduate School of Medicine, Kyoto University, 54 Shogoinkawara cho, Sakyo ku, Kyoto 606 8507, Japan
    Proc Natl Acad Sci U S A 99:383-8. 2002
    ..These results suggest that VEGF cannot only activate endothelial cells directly but also can contribute to robust angiogenesis in vivo by a mechanism that involves up-regulation of its cognate receptor expression...
  44. ncbi Guidance of cell migration by the Drosophila PDGF/VEGF receptor
    P Duchek
    European Molecular Biology Laboratory, Developmental Biology Programme, 69117 Heidelberg, Germany
    Cell 107:17-26. 2001
    ..Intriguingly, the guidance function of PVR is largely redundant with that of EGFR. We present evidence implicating Rac and the Rac activator Mbc/DOCK180/CED-5 as mediators of the guidance signal...
  45. ncbi Caenorhabditis elegans receptors related to mammalian vascular endothelial growth factor receptors are expressed in neural cells
    Cornel Popovici
    Molecular Oncology, INSERM U119, 27 Boulevard Lei Roure, 13009 Marseille, France
    Neurosci Lett 329:116-20. 2002
    ..kinase receptors (RTK) we identified a family of four RTKs which are structurally related to vascular endothelial growth factor receptors (VEGFRs)...
  46. ncbi Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
    L Strizzi
    G D Annunzio University, Department of Oncology and Neuroscience, Clinical Pathology Section, Via dei Vestini 31, 66013 Chieti, Italy
    J Pathol 193:468-75. 2001
    ..In addition, VEGF production could have an impact on patient survival, not only by promoting tumour angiogenesis but also by directly stimulating tumour growth...
  47. ncbi Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues
    R L Kendall
    Department of Cancer Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    J Biol Chem 274:6453-60. 1999
    ..KDR kinase catalyzes phosphotransfer by formation of a ternary complex with ATP and the peptide substrate. We demonstrate that tyrosine kinase antagonists can preferentially inhibit either the unactivated or activated form of the enzyme...
  48. ncbi Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis
    Hinrich Habeck
    Artemis Pharmaceuticals Exelixis Deutschland GmbH, 72076, Tubingen, Germany
    Curr Biol 12:1405-12. 2002
    ..We demonstrate that flk1 is not required for proper vasculogenesis and hematopoiesis in zebrafish embryos. However, the disruption of flk1 impairs the formation or function of vessels generated by sprouting angiogenesis...
  49. ncbi Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma
    Alexander A Parikh
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:720-9. 2003
    ....
  50. ncbi Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors
    Wilmar Castillo-Avila
    Laboratori de Recerca Translacional, Institut Català d Oncologia IDIBELL, Hospital Duran i Reynals, L Hospitalet de Llobregat, Barcelona, Spain
    Clin Cancer Res 15:3384-95. 2009
    ..In the present study, we evaluated the effect of sunitinib, CDDP, or the combination of both drugs using an orthotopic model of human testicular GCT...
  51. ncbi Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:16-24. 2006
    ..SU11248 (sunitinib malate), a small molecule inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clinical activity in patients with metastatic RCC...
  52. pmc A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases
    V Joukov
    Department of Virology, Haartman Institute, University of Helinski, Finland
    EMBO J 15:290-98. 1996
    ..In addition, VEGF-C stimulated the migration of bovine capillary endothelial cells in collagen gel. VEGF-C is thus a novel regulator of endothelia, and its effects may extend beyond the lymphatic system, where Flt4 is expressed...
  53. pmc Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
    R L Kendall
    Department of Biochemistry, Merck Research Laboratories, Rahway, NJ 07065
    Proc Natl Acad Sci U S A 90:10705-9. 1993
    ....
  54. pmc Hypoxia influences the vascular expansion and differentiation of embryonic stem cell cultures through the temporal expression of vascular endothelial growth factor receptors in an ARNT-dependent manner
    Yu Han
    Case Cardiovascular Research Institute, University Hospitals Harrington McLaughlin Heart and Vascular Institute, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Stem Cells 28:799-809. 2010
    ....
  55. ncbi SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
    T A Fong
    SUGEN, Inc, South San Francisco, California 94080, USA
    Cancer Res 59:99-106. 1999
    ..These findings support that pharmacological inhibition of the enzymatic activity of the vascular endothelial growth factor receptor represents a novel strategy for limiting the growth of a wide variety of tumor types...
  56. ncbi A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib
    Thibault de La Motte Rouge
    INSERM, U848, Villejuif, France
    Cancer Res 67:6253-62. 2007
    ..g., Puma, Bax, Bak, caspase-2, etc.) and DNA damage-related proteins (e.g., ERCC1, hTERT) exerted cytoprotective effects. BMS-690514 is a new pan-HER/VEGFR inhibitor that may become an alternative to erlotinib for the treatment of NSCLC...
  57. pmc Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor
    Rizwan Masood
    Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Am J Pathol 160:23-9. 2002
    ..VEGF and VEGF receptors are thus induced in EC-HHV-8 and participate in the transformation. Inhibitors of VEGF may thus modulate the disease process during development and progression...
  58. ncbi Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma
    Yong C Lee
    Department of Internal Medicine, Research Institute of Clinical Medicine, Chonbuk National University Medical School, Chonju, South Korea
    J Immunol 168:3595-600. 2002
    ..Administration of VEGFR inhibitors reduced all these pathophysiological symptoms. These results suggest that VEGF is one of the major determinants of TDI-induced asthma and that the inhibition of VEGF may be a good therapeutic strategy...
  59. ncbi Angiogenesis of breast cancer
    Bryan P Schneider
    Division of Hematology Oncology, Indiana University, 535 Barnhill Dr, RT 473 Indianapolis, IN 46202, USA
    J Clin Oncol 23:1782-90. 2005
  60. ncbi Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia
    Antonella N Witmer
    Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Histochem Cytochem 50:767-77. 2002
    ..One of these functions may be involvement of VEGF in paracrine relations between epithelia and adjacent capillaries...
  61. ncbi Homeostatic modulation of cell surface KDR and Flt1 expression and expression of the vascular endothelial cell growth factor (VEGF) receptor mRNAs by VEGF
    D Wang
    Surgical Oncology Laboratory, Department of Surgery, University of California at San Francisco, San Francisco, California 94143 0790, USA
    J Biol Chem 275:15905-11. 2000
    ....
  62. pmc A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells
    T Takahashi
    Department of Genetics, Institute of Medical Science, University of Tokyo, Minato ku, Tokyo 108 8639, Japan
    EMBO J 20:2768-78. 2001
    ..These findings strongly suggest that autophosphorylation of Y1175 on KDR is crucial for endothelial cell proliferation, and that this region is a new target for anti-angiogenic reagents...
  63. ncbi Non-angiogenic functions of VEGF in breast cancer
    Arthur M Mercurio
    Department of Cancer Biology and the Cancer Center, University of Massachusetts Medical School, Worcester, MA 01605, USA
    J Mammary Gland Biol Neoplasia 10:283-90. 2005
    ..These findings imply that VEGF and VEGF receptor-based therapeutics, in addition to targeting angiogenesis, may also target tumor cells directly...
  64. ncbi Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor
    Tadashi Ogawa
    Department of Biochemistry and Molecular Pathophysiology, University of Occupational and Environmental Health, School of Medicine, Kitakyusyu, Japan
    Cancer Gene Ther 9:633-40. 2002
    ..The combined usage of sVEGFR plus sFGFR1 suppressed tumor growth in all cancer cell lines tested, suggesting possible effectiveness of this strategy against a wide range of cancers...
  65. ncbi High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
    B Millauer
    Department of Molecular Biology, Max Planck Institute for Biochemistry, Martinsried, Federal Republic of Germany
    Cell 72:835-46. 1993
    ....
  66. pmc Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3
    T Makinen
    Molecular Cancer Biology Laboratory and Ludwig Institute for Cancer Research, and Helsinki University Hospital, Biomedicum Helsinki, University of Helsinki, FIN 00014 Helsinki, Finland
    EMBO J 20:4762-73. 2001
    ..The culture of isolated lymphatic endothelial cells should now allow further studies of the molecular properties of these cells...
  67. ncbi Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1
    E Landgren
    Dept of Medical and Physiol Chemistry Biomedical Center, Uppsala, Sweden
    Oncogene 16:359-67. 1998
    ....
  68. ncbi Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division
    Joseph B Kearney
    Program in Genetics and Molecular Biology, Department of Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Blood 99:2397-407. 2002
    ..Taken together, these data show that flt-1 normally modulates vascular growth by controlling the rate of endothelial cell division both in vitro and in vivo...
  69. ncbi VEGF receptor signaling in tumor angiogenesis
    G McMahon
    SUGEN, Inc, South San Francisco, California 94080, USA
    Oncologist 5:3-10. 2000
    ..A number of these modalities are under investigation in clinical studies to evaluate their potential to treat human cancers...
  70. ncbi A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis
    F Shalaby
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Cell 89:981-90. 1997
    ....
  71. ncbi Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans
    A Sawano
    Department of Genetics and Department of Clinical Oncology, Institute of Medical Science, University of Tokyo, Japan
    Blood 97:785-91. 2001
    ..These results strongly suggest that Flt-1 is a novel cell surface marker as well as a biologically functional molecule for monocyte-macrophage lineages in humans...
  72. ncbi Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice
    Daniel Zips
    Department of Radiation Oncology, Medical Faculty Carl Gustav Carus, University of Technology Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
    Int J Radiat Oncol Biol Phys 61:908-14. 2005
    ..To test the latter hypothesis, local tumor control experiments were performed...
  73. ncbi Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus through interaction with Daxx
    Yuko Murakami
    Department of Bioactive Molecules, National Institute of Infectious Diseases, Tokyo 162, Japan
    J Biol Chem 281:28113-21. 2006
    ..These results suggested that LANA contributes to a high expression of VEGF receptors in KS lesion by interfering with the interaction between Daxx and Ets-1...
  74. ncbi Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation
    Pipsa Saharinen
    Molecular Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum Helsinki and Helsinki University Central Hospital, University of Helsinki, P O B 63 Haartmaninkatu 8, 00014 Helsinki, Finland
    Trends Immunol 25:387-95. 2004
  75. pmc Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth
    C Hess
    Department of Radiation Oncology, University Hospital Zurich, CH 8091 Zurich, Switzerland
    Br J Cancer 85:2010-6. 2001
    ....
  76. ncbi Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803
    X Tian
    Department of Biochemistry and Molecular Biology, Beijing Institute for Cancer Research, Peking University School of Oncology, Beijing, 100034, People s Republic of China
    Biochem Biophys Res Commun 286:505-12. 2001
    ....
  77. ncbi Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors
    R Masood
    Department of Medicine, University of Southern California School of Medicine, Los Angeles, CA, USA
    Blood 98:1904-13. 2001
    ..In VEGFR-2-expressing tumors, VEGF inhibition may have dual functions: direct inhibition of tumor cell growth and inhibition of angiogenesis...
  78. ncbi Inhibition of tyrosine phosphorylation of vascular endothelial growth factor receptors in human umbilical vein endothelial cells: a potent anti-angiogenic lipid-rich extract from shark
    Lan Yuan
    Bioactivity Investigation Group, Wellington School of Medicine and Health Sciences, Wellington, New Zealand
    J Med Food 10:657-61. 2007
    ..These results demonstrated that SMO might interfere with or block the binding of VEGF with its receptors, and thereby inhibit the VEGF receptor(s) signal transduction pathway and so inhibit angiogenesis...
  79. ncbi Developmental control of blood cell migration by the Drosophila VEGF pathway
    Nam K Cho
    Howard Hughes Medical Institute, Department of Biochemistry, Stanford University, Stanford, CA 94305, USA
    Cell 108:865-76. 2002
    ..The results suggest that the Drosophila VEGF pathway guides developmental migrations of blood cells, and we speculate that the ancestral function of VEGF pathways was to guide blood cell movement...
  80. pmc Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding domain is important for vasculogenesis and angiogenesis in mice
    Sachie Hiratsuka
    Division of Genetics, Institute of Medical Science, University of Tokyo, Tokyo 108 8639, Japan
    Mol Cell Biol 25:346-54. 2005
    ..These results strongly suggest that the membrane-fixed ligand-binding region of VEGFR1 traps VEGF for the appropriate regulation of VEGF signaling in vascular endothelial cells during early embryogenesis...
  81. pmc Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer
    Keiko Shibuya
    Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:1534-43. 2007
    ....
  82. ncbi Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing vascular endothelial growth factor expression
    Kyung S Lee
    Department of Internal Medicine, Research Center for Allergic Immune Diseases, Chonbuk National University Medical School, 634 18 Keumamdong, Jeonju 561 712, South Korea
    J Allergy Clin Immunol 114:1093-9. 2004
    ..However, the mechanisms by which cysLTs induce increased vascular permeability are not clearly understood...
  83. ncbi NCK and PAK participate in the signaling pathway by which vascular endothelial growth factor stimulates the assembly of focal adhesions
    K V Stoletov
    Departments of Medicine and Pathology, Albert Einstein College of Medicine, Bronx, New York 10461, USA
    J Biol Chem 276:22748-55. 2001
    ..Inhibition of NCK protein expression using antisense oligonucleotides led to the inhibition of both VEGF-induced focal adhesion assembly and VEGF-induced cell migration, demonstrating a necessary role of NCK in these cellular responses...
  84. ncbi Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis
    Philippe O Van Trappen
    Department of Gynaecological Oncology, Cancer Research UK Translational Oncology Laboratory, St Bartholomew s and the Royal London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK
    J Pathol 201:544-54. 2003
    ..These results suggest that in cervical carcinogenesis a switch to the lymphangiogenic phenotype may occur at the stage of CIN 3...
  85. ncbi Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors
    Tammo Ostendorf
    Division of Nephrology and Immunology, University Hospital Aachen, Pauwelsstrasse 30, D 52074 Aachen, Germany
    J Am Soc Nephrol 15:2307-19. 2004
    ..These data identify iNOS-derived NO production as the first in vivo regulator of the glomerular VEGF system and as an important mechanism promoting glomerular healing...
  86. ncbi The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma
    A Sawano
    Institute of Medical Science, University of Tokyo, Minato ku, Tokyo, 108, Japan
    Biochem Biophys Res Commun 238:487-91. 1997
    ..These results strongly suggest that Tyr-1169 on Flt-1 is a major binding site for PLCgamma and important for Flt-1 signal transduction within the cell...
  87. ncbi Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system
    Omolara O Ogunshola
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Biol Chem 277:11410-5. 2002
    ..Thus, our in vitro data support a role for neuronal VEGF in both paracrine and autocrine signaling in the maintenance of neurons and endothelia in the central nervous system...
  88. ncbi Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma
    C A Boocock
    Department of Obstetrics and Gynaecology, University of Cambridge, Rosie Maternity Hospital, England
    J Natl Cancer Inst 87:506-16. 1995
    ..The known human receptors for VEGF, flt and KDR, are both cell surface tyrosine kinases and are expressed predominantly on endothelial cells. Acting through these receptors, VEGF may stimulate angiogenesis and promote tumor progression...
  89. ncbi Vascular endothelial growth factor in the lung
    Norbert F Voelkel
    University of Colorado Health Sciences Center, Pulmonary and Critical Care Division, 4200 E Ninth Ave, C272, Denver, CO 80262, USA
    Am J Physiol Lung Cell Mol Physiol 290:L209-21. 2006
    ..Here we provide a comprehensive overview of the rapidly expanding literature...
  90. ncbi Update on clinical trials targeting vascular endothelial growth factor in cancer
    Emily K Bergsland
    University of California San Francisco Comprehensive Cancer Center, 1600 Divisidero, 4th Floor, San Francisco, CA 94115, USA
    Am J Health Syst Pharm 61:S12-20. 2004
    ..The clinical trials of vascular endothelial growth factor (VEGF) inhibitors are discussed...
  91. ncbi Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors
    Jung Hyun Park
    Laboratory for Cancer Epigenetics and Experimental Therapeutics, Cancer Research Institute, Seoul, Republic of Korea
    Biochem Biophys Res Commun 368:318-22. 2008
    b>Vascular endothelial growth factor receptors (VEGFRs) perform pivotal roles in both tumor growth and angiogenesis...
  92. ncbi Modulation of vascular endothelial growth factor receptors in melanocytes
    Ellen J Kim
    Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
    Exp Dermatol 14:625-33. 2005
    ..Prolonged culture (>8 weeks) in the presence of phorbol ester abrogates VEGFR-2 expression, explaining previous reports that Mc do not express VEGFR-1 and VEGFR-2. These data suggest that VEGF may play a role in Mc behavior in skin...
  93. ncbi Effect of heparin affin regulatory peptide on the expression of vascular endothelial growth factor receptors in endothelial cells
    G Kokolakis
    Laboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece
    In Vivo 20:629-35. 2006
    ..In the present work, the effect of human recombinant HARP on the expression of the vascular endothelial growth factor (VEGF) receptors KDR, Flt-1 and neuropilin-1 was studied in cultured human umbilical vein endothelial cells (HUVEC)...
  94. ncbi Regulation of angiogenesis: wound healing as a model
    Sabine A Eming
    Department of Dermatology, University of Cologne, Joseph Stelzmann Street 9, 50931 Koln, Germany
    Prog Histochem Cytochem 42:115-70. 2007
    ..The article provides a rationale for targeting the angiogenic response in order to modulate the outcome of the healing response...
  95. ncbi Expression of vascular endothelial growth factor receptors in bovine cystic follicles
    N Isobe
    Graduate School of Biosphere Science, Hiroshima University, Higashi Hiroshima, Japan
    Reprod Domest Anim 43:267-71. 2008
    ....
  96. pmc Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    G Bergers
    Department of Biochemistry and Biophysics, University of California, 513 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Cell Biol 2:737-44. 2000
    ..Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch...
  97. ncbi Expression of vascular endothelial growth factor receptors in experimental otitis media in the rat
    Sung Won Chae
    Department of Otolaryngology Head and Neck Surgery, Korea University College of Medicine, Seoul, South Korea
    Acta Otolaryngol 123:559-63. 2003
    ..The purpose of this study was to investigate the expression of three forms of VEGFR (-1, -2 and -3) in an endotoxin-induced rat model of OME...
  98. pmc Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer
    T Tokunaga
    Department of Pathology, Tokai University School of Medicine, Isehara, Kanagawa, Japan
    Br J Cancer 77:998-1002. 1998
    ..006). These observations suggest that the aberrant type 3 expression pattern of VEGF189 mRNA isoforms is correlated with liver metastasis, M stage, and poor prognosis in colon cancer...
  99. ncbi Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
    J E Park
    Genentech, Inc, South San Francisco, California 94080
    J Biol Chem 269:25646-54. 1994
    ..Purified PIGF isoforms had little or no direct mitogenic or permeability-enhancing activity. However, they were able to significantly potentiate the action of low concentrations of VEGF in vitro and, more strikingly, in vivo...
  100. ncbi Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation
    Lydia Nakopoulou
    Department of Pathology, Medical School, University of Athens, Greece
    Hum Pathol 33:863-70. 2002
    ..On the other hand, the inverse correlation of Flk-1 with TIMP-1 mRNA in intratumoral stromal cells supports the notion that TIMP-1 may have an inhibitory role on angiogenesis...
  101. ncbi Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis
    B A Keyt
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 271:5638-46. 1996
    ..Furthermore, this mutational analysis implicates KDR, but not FLT-1, in VEGF induction of endothelial cell proliferation...

Research Grants72

  1. Expression of sFlt1 and its function in the glomerular endothelium
    Christie P Thomas; Fiscal Year: 2013
    ....
  2. Mechanisms and Consequences of Reduced PPAR gamma in Pulmonary Hypertension
    C Michael Hart; Fiscal Year: 2013
    ..The results of this proposal can thereby define novel and effective therapeutic strategies to regulate programs of gene expression involved in PH pathogenesis. ..
  3. Phosphotyrosine signaling pathways controlling tracheal tube geometry
    KAI G ZINN; Fiscal Year: 2013
    ..We can also analyze tyrosine phosphorylation of the proteins and determine if they physically interact with each other in the embryo. ..
  4. Histone Chaperones in Angiogenesis
    Soumen Paul; Fiscal Year: 2012
    ..For example, transcriptional mechanisms that regulate vascular endothelial growth factor receptors (VEGFRs) expression during angiogenesis are largely unknown...
  5. Mechanisms of Angiogenesis in Retinopathy of Prematurity
    Mary Elizabeth Hartnett; Fiscal Year: 2009
    ..g., dihydroethidium);and NADPH oxidase activation. ..
  6. Mechanisms of Angiogenesis of Retinopathy of Prematurity
    MARY ELIZABETH RUTH HARTNETT; Fiscal Year: 2013
    ..g., dihydroethidium);and NADPH oxidase activation. ..
  7. ANGIOTENSIN II SIGNAL TRANSDUCTION
    Bradford C Berk; Fiscal Year: 2012
    ..PUBLIC HEALTH RELEVANCE: The healing of tissues after surgery or trauma is critical for long-term survival. The proposed work will study novel mechanisms by which blood vessels grow in response to tissue injury. ..
  8. Evaluating Novel Multi-kinase Peptide Inhibitors as a Treatment for Rheumatoid Ar
    DAVID MEN HWEI TSAI; Fiscal Year: 2013
    ..The long term goal of this project is to develop a safe, effective, and cost-efficient therapy to treat RA. ..
  9. VEGF Regulation of Hepatic Erythropoietin Synthesis
    Calvin Kuo; Fiscal Year: 2009
    ....
  10. Inhibition of angiogenesis by thrombospondin-1 (A2)
    JOHN W LAWLER; Fiscal Year: 2012
    ..The goal of the proposed study is to determine how proteins that the body normally uses to limit blood vessel growth work. This knowledge will be used to develop therapeutic approaches for the treatment of cancer. ..
  11. CEACAM1: A link between metabolic and cardiovascular diseases
    Sonia M Najjar; Fiscal Year: 2013
    ..Answering these questions will delineate new CEACAM1-dependent mechanisms underlying atherosclerosis along the liver/endothelial cell axis, and pinpoint sites of pharmacologic intervention. ..
  12. Role of Monocyte Chemoattractant Protein (MCP)-1 in Liver Regeneration
    KRISTEN ANDREA MITCHELL; Fiscal Year: 2010
    ..Finally, this project provides an opportunity for undergraduates at Boise State University to participate in biomedical research and gain an appreciation of the complex regulatory mechanisms that govern regeneration. ..
  13. Improving CBF through direct control of CSF pulsations
    MARK GREGORY LUCIANO; Fiscal Year: 2010
    ....
  14. Long Term Implications of Preeclampsia: Role of Obesity vs sFlt-1 Overexpression
    Egle Bytautiene; Fiscal Year: 2009
    ..This model will also provide an experimental tool for investigating mechanisms of CVD and the well established gender differences in health and disease. ..
  15. Protein Kinase D2 Function and Signaling in Angiogenesis
    Hua Tang; Fiscal Year: 2012
    ..We anticipate that these studies will provide a strong rationale for PKD2 as a novel drugable target for therapeutic intervention in angiogenesis- related human diseases. ..
  16. Novel Protective Antiapoptotic Action of Alpha 1-Antitrypsin In Emphysema
    Rubin M Tuder; Fiscal Year: 2011
    ..abstract_text> ..
  17. The Role of Galectins in Corneal Hem- and Lymphangiogenesis
    Noorjahan Panjwani; Fiscal Year: 2013
    ....
  18. Novel ex-vivo Immunoadsorption Therapy to Treat Preeclampsia
    Woo Joo; Fiscal Year: 2013
    ..The total market for Aggamin's therapeutic product to treat severe early-onset PE cases in the US is estimated at $0.5-1.5 billion. ..
  19. Cellular Mechanisms of Amniotic Fluid Volume Regulation
    Cecilia Y Cheung; Fiscal Year: 2013
    ..Further, the signal transduction cascades that mediate these transport events will be investigated. The findings will lead to an improved understanding of the etiology of amniotic fluid volume abnormalities. ..
  20. A phase Ib/II study of AZD2171 and radiation for new brain metastases from NSCLC
    APRIL FITZSIMMONS EICHLER; Fiscal Year: 2010
    ..Brain metastases are often fatal, and new therapies are desperately needed. We propose to study AZD2171, an experimental therapy that acts on tumor blood supply, in lung cancer patients with brain metastases. ..
  21. CellTrap: A novel solid phase platform for analysis of stem/progenitor cells
    NICANOR I contact MOLDOVAN; Fiscal Year: 2010
    ..The project will have both short term economic impact and long term sustainability by creation of a company for commercialization of the assay kit. ..
  22. Enterovirus Vectors with Respiratory Tropism for Cancer Immunotherapy
    Matthias Gromeier; Fiscal Year: 2010
    ..We are testing a new type of vaccine based on a common cold- causing virus targeting these pathways. We will evaluate our immunization technology in a novel animal model for the common cold. ..
  23. Focal Adhesion Kinase - Tumor Biology and Therapeutics
    William G Cance; Fiscal Year: 2013
    ..Thus, this application will provide novel molecular cancer therapeutics that target the focal adhesion kinase. ..
  24. Corneal Lymphatics &Adaptive Immunity
    DANIEL J CARR; Fiscal Year: 2013
    ..abstract_text> ..
  25. Novel multivalent/multifunctional agents derived from a humanized anti-insulin-li
    Thomas M Cardillo; Fiscal Year: 2010
    ....
  26. Therapeutic Evaluation of Magnetic Nanoprobes Specific for Malignant Tumor Marker
    Rheal A Towner; Fiscal Year: 2010
    ..Studying a potentially effective anti- tumor therapeutic agent, as well as developing novel in vivo diagnostic and predictive procedures may significantly impact patient prognosis and survivability in the future. ..
  27. VEGF receptor-1-mediated protection in dilated cardiomyopathy
    Fabio A Recchia; Fiscal Year: 2013
    ....
  28. Non-canonical VEGF receptor signaling regulates retinal neovascularization
    MICHAEL EDWIN BOULTON; Fiscal Year: 2012
    ..Understanding this novel non-canonical VEGF signalling pathway(s) will provide new information on angiogenesis and allow development of a sustainable treatment strategy for AMD and diabetic retinopathy. ..
  29. The connection between Notch signaling and VEGFR1 in angiogenesis
    HASINA HAMILTON OUTTZ; Fiscal Year: 2011
    ....
  30. Mechanisms for Arsenic-Induced Vascular Disease
    Aaron Barchowsky; Fiscal Year: 2012
    ..Targeted delivery of RhoA or Rac1-GTPase siRNA and selective GT Pase activity assays will be used to dissect the roles of Rho family members in As (III)-stimulated LSEC capillarization. ..
  31. Understanding Mechanisms of Resistance to Anti-angiogenic Treatments
    Ali Syed Arbab; Fiscal Year: 2013
    ..We expect the results of this experimental proposal will shade lights on the mechanisms of resistance to anti- angiogenic treatments and allow clinician to change the strategy of future treatment for GBM or other solid tumors. ..
  32. Quantitative Biomarker Imaging for Early Therapy Response Assessment in Cancer
    James M Mountz; Fiscal Year: 2013
    ..Development and use of quantitative imaging for early therapy assessment will greatly facilitate cancer patient management by sparing patients from weeks or months of toxicity and ineffective treatment. ..
  33. Opioid Activity in Endothelium in Sickle Cell Disease
    Kalpna Gupta; Fiscal Year: 2012
    ..If our hypotheses are true, this project may lead to the development of an effective treatment for painful leg ulcers in sickle cell disease. ..
  34. Placental Insufficiency in Transgenic Mouse Model of Preeclampsia and IUGR
    TERRY KNUD MORGAN; Fiscal Year: 2013
    ..Our results will help us better understand the underlying pathology of these serious human diseases and are the first steps toward future studies investigating molecular mechanisms and potential applications in women. ..
  35. Control of Hedgehog Signal Transduction by Neuropilin
    Matthew P Scott; Fiscal Year: 2013
    ..Using newly created lentiviruses, which encode specific inhibiting RNAs that block the nrp genes, we will infect primary cultures of Hh-responsive cells and monitor effects on Hh target gene expression. ..
  36. Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy
    Dai Fukumura; Fiscal Year: 2012
    ..This project will advance the basic understanding of NO-mediated vessel maturation and help develop novel strategies to improve the delivery of drugs and oxygen to tumors. ..
  37. CB1 Receptor-Mediated Tyrosine Phosphorylation of FAK and ERK in Neurons
    George D Dalton; Fiscal Year: 2012
    ....
  38. IVUS Detection of Rupture Prone Plaques
    Marvin M Doyley; Fiscal Year: 2013
    ....
  39. Distinct Pathways of VPF/VEGF Receptors
    Debabrata Mukhopadhyay; Fiscal Year: 2013
    ..Lastly, the proposed studies will expand our understanding of VEGF-A signaling as it relates to other VEGF-responsive cell types including circulating progenitor cells, bone cells, and neuronal progenitors. ..
  40. Angiogenesis-targeting therapy for glioblastoma
    Tracy T Batchelor; Fiscal Year: 2013
    ....
  41. The Mechanisms of GM-CSF Inhibition of Breast Cancer Growth and Metastasis
    TIMOTHY EUBANK; Fiscal Year: 2009
    ....
  42. Functional characterization of a novel adult renal progenitor cell population
    TROY D CAMARATA; Fiscal Year: 2011
    ..This new information will aid in the development of novel therapies for acute and chronic forms of kidney disease and will provide critical information to the fields of renal biology as well as organ regeneration. ..
  43. NF-kB mediated induction of VEGFR-3 and new lymphatic vessels in breast cancer
    Sophia Ran; Fiscal Year: 2013
    ..Because metastasis is the primary cause of mortality from cancer, these studies have the potential to significantly improve health outcomes in a large number of cancer patients. ..
  44. Cell-targeted drug delivery for the treatment of pulmonary arterial hypertension
    Masahiko Oka; Fiscal Year: 2012
    ..abstract_text> ..
  45. Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy
    Kenneth I Ataga; Fiscal Year: 2013
    ..abstract_text> ..
  46. Role of a9b1 Integrin in lymphangiogenesis
    Nicholas E Vlahakis; Fiscal Year: 2010
    ..End of Abstract) ..
  47. Activation and Signaling Mechanism of the RET Tyrosine Kinase Receptor
    JENNIFER MARIE CHOW; Fiscal Year: 2013
    ..Working together, the candidate and her sponsor have developed a highly effective plan for how to achieve the training she will need to meet her long-term career objectives. ..
  48. Role of Syntaxin 6 Regulated Post-Golgi Trafficking in Angiogenesis
    Amit Choudhury; Fiscal Year: 2012
    ..By studying and understanding the trafficking of angiogenesis-regulatory molecules, we may identify a novel target for therapy. ..
  49. Models to predict prognosis and benefit from adjuvant therapy in renal cell carci
    Harriet M Kluger; Fiscal Year: 2013
    ..We will use a newly developed method of automated analysis of target levels from biopsy specimens, and in the future we will be able to apply this technology to other diseases and other targeted therapies. ..
  50. VEGF regulation of neurogenesis
    DIANE CATHERINE DARLAND; Fiscal Year: 2011
    ..The current proposal will address specifically a role for VEGF in regulating the survival, proliferation, and differentiation of neural stem cells in the context of the developing vasculature. ..
  51. Therapeutic Angiogenesis for Erectile Dysfunction
    BRIAN ANNEX; Fiscal Year: 2009
    ..In this renewal, we propose to identify the mechanism for hypercholesterolemia induced vascular injury as well as how to employ information gained in the studies to advance potential treatments for ED...
  52. The effects of the unfolded protein response on medulloblastoma
    Wensheng Lin; Fiscal Year: 2013
    ..The knowledge gained from these studies will have important implications for MB tumorigenesis and may lead to novel therapeutic strategies for treating this disease. ..
  53. Interaction of Angiopoietin & VEGF signals in arthritis
    P Charles Lin; Fiscal Year: 2010
    ....
  54. Regulation of Wnt signaling by LPP3 (PAP2b) during angiogenesis
    Kishore K Wary; Fiscal Year: 2013
    ..The results of these investigations may reveal new therapeutic strategies to regulate angiogenesis, and the apoptotic properties of endothelial and tumor cells. ..
  55. Investigation of the VEGFR/Integrin cytoplasmic domains interaction.
    Olga Vinogradova; Fiscal Year: 2011
    ..Moreover, our structural approach should contribute to the development of new therapeutic agents designed to inhibit integrin (and other receptors) cytoplasmic domain protein-protein interactions. ..
  56. Early Detection of Pancreatic Cancer with Targeted Contrast-enhanced Ultrasound
    JUERGEN KARL WILLMANN; Fiscal Year: 2010
    ..Following successful outcome with our current study, we anticipate rapid translation of this technique into the clinic to expand patient survival and improve patient care by diagnosing this deadly disease much earlier. ..
  57. Keratinocyte responses to vascular endothelial growth factor in carcinogenesis
    Traci A Wilgus; Fiscal Year: 2012
    ..The information resulting from these studies could lead to a better understanding about the development and growth of skin tumors, and could also result in the development of better ways to prevent and treat skin cancer. ..
  58. Mechanisms of thymide phosphorylase angiogenesis
    Edward L Schwartz; Fiscal Year: 2010
    ..This information could lead to new drug treatments for cancer. ..
  59. Tie Tek Modulation of Cardiac Development
    H Scott Baldwin; Fiscal Year: 2013
    ....
  60. Regulation of Integrins in Neovasculature Development
    Tatiana V Byzova; Fiscal Year: 2012
    ..abstract_text> ..
  61. VEGFR-2 Targeted Imaging
    Zhen Cheng; Fiscal Year: 2011
    ..The success of this project will allow translation of the new imaging probe into clinic for lesion detection and monitoring therapeutic response. ..
  62. Pericyte-endothelial cross talk in vascular stability after kidney injury
    STUART JAMES SHANKLAND; Fiscal Year: 2013
    ..Determine the role of pericyte-derived TIMP3 and ADAMTS1 in regulation of microvascular stability and VEGF receptor signaling Aim 3. Define pericyte-derived VEGFA as a determinant of spontaneous &induced kidney disease progression. ..
  63. Ocular Lymphangiogenesis
    DANIEL J CARR; Fiscal Year: 2010
    ....
  64. Angiotensin II and diabetic retinopathy
    ALFONSO SCICLI; Fiscal Year: 2006
    ..These studies will help understand the role of the RAS in diabetic retinopathy. ..
  65. ENDOTHELIAL CELL AUTOIMMUNITY IN DIABETIC RETINOPATHY
    Ramesh Nayak; Fiscal Year: 2001
    ..This will be the first demonstration of an effector mechanism underlying an immunogenetic association with diabetic retinopathy. ..
  66. Novel Combretastatin A4 analogs for Treatment of Retinal Neovascularization
    Danyang Chen; Fiscal Year: 2007
    ..This proof-of-concept study represents the first step in developing new anti-angiogenic drugs using these CA4 analogs. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  67. VEGF-dependent and - Independent Anti-angiogenic Therapy
    Calvin Kuo; Fiscal Year: 2006
    ..Moreover, these humanized receptors will be expressed from regulated adenoviruses to confer an additional degree of safety as a prelude to eventual clinical use. ..
  68. Role of VEGF in Glomerular Endothelial Health & Diseases
    S Karumanchi; Fiscal Year: 2007
    ..abstract_text> ..
  69. Vascular Heterogeneity Determination by Marrow Progenit*
    Shahin Rafii; Fiscal Year: 2006
    ..These studies will lay the foundation for using BM-marrow derived cells for therapeutic cell therapy to enhance organ (i.e. lung, marrow) revascularization. ..
  70. KDR--A NOVEL FUNCTIONAL HEMATOPOIETIC STEM CELL MARKER
    Cesare Peschle; Fiscal Year: 2004
    ....
  71. Mechansim of tea catechin's inhibition of angiogenesis
    Mohsen Meydani; Fiscal Year: 2003
    ..abstract_text> ..
  72. Analysis of the Novel Kinase ROR2: A New Molecular Target in Renal Cell Carcinoma
    Tricia M Wright; Fiscal Year: 2010
    ..The long term goal of this study is not only to analyze the importance of ROR2 in RCC but also to use the gained knowledge of ROR2 function in the hopes of finding inhibitors that can be used clinically for treating RCC. ..